A detailed history of Vaughan & CO Securities, Inc. transactions in Pfizer Inc stock. As of the latest transaction made, Vaughan & CO Securities, Inc. holds 27,570 shares of PFE stock, worth $784,642. This represents 0.49% of its overall portfolio holdings.

Number of Shares
27,570
Previous 19,200 43.59%
Holding current value
$784,642
Previous $532,000 44.92%
% of portfolio
0.49%
Previous 0.34%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$25.26 - $29.6 $211,426 - $247,752
8,370 Added 43.59%
27,570 $771,000
Q1 2024

May 01, 2024

SELL
$25.89 - $29.73 $44,479 - $51,076
-1,718 Reduced 8.21%
19,200 $532,000
Q4 2023

Jan 26, 2024

BUY
$26.13 - $33.94 $221,582 - $287,811
8,480 Added 68.18%
20,918 $602,000
Q1 2023

Apr 18, 2023

BUY
$39.39 - $51.28 $15,007 - $19,537
381 Added 3.16%
12,438 $507,000
Q4 2022

Feb 02, 2023

SELL
$41.75 - $54.5 $12,441 - $16,241
-298 Reduced 2.41%
12,057 $618,000
Q3 2022

Oct 21, 2022

SELL
$43.76 - $53.42 $2,100 - $2,564
-48 Reduced 0.39%
12,355 $541,000
Q1 2022

Apr 21, 2022

SELL
$45.75 - $56.69 $20,404 - $25,283
-446 Reduced 3.47%
12,403 $642,000
Q4 2021

Jan 27, 2022

SELL
$41.32 - $61.25 $13,883 - $20,580
-336 Reduced 2.55%
12,849 $759,000
Q3 2021

Oct 15, 2021

SELL
$39.25 - $50.42 $8,281 - $10,638
-211 Reduced 1.58%
13,185 $567,000
Q4 2020

May 11, 2021

SELL
$33.47 - $42.56 $11,078 - $14,087
-331 Reduced 2.41%
13,396 $493,000
Q3 2020

May 10, 2021

SELL
$31.75 - $37.25 $14,541 - $17,060
-458 Reduced 3.23%
13,727 $504,000
Q4 2019

Feb 04, 2020

BUY
$32.92 - $37.36 $466,970 - $529,951
14,185 New
14,185 $527,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $160B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Vaughan & CO Securities, Inc. Portfolio

Follow Vaughan & CO Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vaughan & CO Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vaughan & CO Securities, Inc. with notifications on news.